Gapping up
In reaction to strong earnings/guidance: RT +4.6%, RTIX +2.8%, TSM +2.4%, CRUS +2.1%, FIVE +1.2%, (Five Below raises Q4 rev guidance and narrows Q4 EPS guidance; holiday comps +4.1%), BBBY +1.1%, URBN +0.6%, (Urban Outfitters reports Nov/Dec total company net sales were flat y/y, comparable retail segment (including direct- to-consumer channel) net sales -2%), .
M&A news: SHPG +2.6% (Potential Shire (SHPG) acquisition of BXLT at $48/share), BXLT +1.8% (Potential Shire (SHPG) acquisition of BXLT at $48/share)
Select China related names showing strength: YNDX +3.9%, WBAI +3.4%, CHU +2.8%, CHL +2.6%, HSBC +1.9%.
Select alt energy stocks trading higher: FCEL +12.8%, JKS +8.9%, CPST +7.1%, CSIQ +5.7%
Select oil/gas related names showing strength: CHK +3.6%, PBR +3.1%, SDRL +2.1%, DVN +1.6%, KMI +1.4%, COP +0.8%
Other news: SIEN +40.8% (Sientra sends letter to surgeons regarding the independent third-party testing of Sientra's products, the submission of such test results to the FDA and other business updates), XBIT +18.1% (completes data analysis for its Phase III European study), ATHX +14.6% (Athersys and Healios form alliance focusing on development and commercialization of regenerative medicine products for stroke in Japan), BCLI +10% (still checking), NGL +7.7% (announced that it has entered into an agreement with an affiliate of ArcLight Capital Partners to sell TransMontaigne GP LLC for $350 mln in cash), WTW +4.6% (cont volatility), DDD +4.2% (likely due to CES presentation), MNTA +4.1% (enters into an exclusive global collaboration agreement with Mylan (MYL)),ARDX +4% (prices 7.5 mln shares of its common stock at $10.00 per share), ARIA +3.8% (Ariad Pharm and its partner Otsuka Pharma submit NDA to the Japanese Pharmaceuticals and Medical Devices Agency seeking approval for Iclusig), FOMX +3.2% (announces positive results from a Phase 1 maximum use pharmacokinetics study of FMX-101, top line results indicate that the relative bioavailability of FMX-101 was more than 100x lower than that for Solodyn), GPRO +2.6% (cont vol pre-mkt), TWX +2.6% (could be forced to pursue a sale, or spin-off its HBO unit by activist shareholders, according to the NYPost), VRX +2.2% (cont vol pre-mkt), F +2.1% (reports Ford China sold a record 1.1 mln vehicles in 2015; December sales set a record, up 27%), CRH +1.4% (provides strategy update; confirms total disposal proceeds of EUR1 bln for 2015), NXPI +1.3% (following CRUS guidance)
Analyst comments: SGNL +17.6% (initiated with a Buy at Rodman & Renshaw; tgt $4 on favorable MyPRS view), SUNE +12.6% (upgraded to Hold from Sell at Axiom Capital), ARC +2.3% (initiated with a Buy at B. Riley & Co), PHM +1.7% (upgraded to Outperform from Mkt Perform at Raymond James), AA +1.7% (upgraded to Outperform from Neutral at Macquarie), FL +1.5% (upgraded to Buy from Neutral at BofA/Merrill), MSFT +1.1% (initiated with an Outperform at BMO Capital
)
In reaction to strong earnings/guidance: RT +4.6%, RTIX +2.8%, TSM +2.4%, CRUS +2.1%, FIVE +1.2%, (Five Below raises Q4 rev guidance and narrows Q4 EPS guidance; holiday comps +4.1%), BBBY +1.1%, URBN +0.6%, (Urban Outfitters reports Nov/Dec total company net sales were flat y/y, comparable retail segment (including direct- to-consumer channel) net sales -2%), .
M&A news: SHPG +2.6% (Potential Shire (SHPG) acquisition of BXLT at $48/share), BXLT +1.8% (Potential Shire (SHPG) acquisition of BXLT at $48/share)
Select China related names showing strength: YNDX +3.9%, WBAI +3.4%, CHU +2.8%, CHL +2.6%, HSBC +1.9%.
Select alt energy stocks trading higher: FCEL +12.8%, JKS +8.9%, CPST +7.1%, CSIQ +5.7%
Select oil/gas related names showing strength: CHK +3.6%, PBR +3.1%, SDRL +2.1%, DVN +1.6%, KMI +1.4%, COP +0.8%
Other news: SIEN +40.8% (Sientra sends letter to surgeons regarding the independent third-party testing of Sientra's products, the submission of such test results to the FDA and other business updates), XBIT +18.1% (completes data analysis for its Phase III European study), ATHX +14.6% (Athersys and Healios form alliance focusing on development and commercialization of regenerative medicine products for stroke in Japan), BCLI +10% (still checking), NGL +7.7% (announced that it has entered into an agreement with an affiliate of ArcLight Capital Partners to sell TransMontaigne GP LLC for $350 mln in cash), WTW +4.6% (cont volatility), DDD +4.2% (likely due to CES presentation), MNTA +4.1% (enters into an exclusive global collaboration agreement with Mylan (MYL)),ARDX +4% (prices 7.5 mln shares of its common stock at $10.00 per share), ARIA +3.8% (Ariad Pharm and its partner Otsuka Pharma submit NDA to the Japanese Pharmaceuticals and Medical Devices Agency seeking approval for Iclusig), FOMX +3.2% (announces positive results from a Phase 1 maximum use pharmacokinetics study of FMX-101, top line results indicate that the relative bioavailability of FMX-101 was more than 100x lower than that for Solodyn), GPRO +2.6% (cont vol pre-mkt), TWX +2.6% (could be forced to pursue a sale, or spin-off its HBO unit by activist shareholders, according to the NYPost), VRX +2.2% (cont vol pre-mkt), F +2.1% (reports Ford China sold a record 1.1 mln vehicles in 2015; December sales set a record, up 27%), CRH +1.4% (provides strategy update; confirms total disposal proceeds of EUR1 bln for 2015), NXPI +1.3% (following CRUS guidance)
Analyst comments: SGNL +17.6% (initiated with a Buy at Rodman & Renshaw; tgt $4 on favorable MyPRS view), SUNE +12.6% (upgraded to Hold from Sell at Axiom Capital), ARC +2.3% (initiated with a Buy at B. Riley & Co), PHM +1.7% (upgraded to Outperform from Mkt Perform at Raymond James), AA +1.7% (upgraded to Outperform from Neutral at Macquarie), FL +1.5% (upgraded to Buy from Neutral at BofA/Merrill), MSFT +1.1% (initiated with an Outperform at BMO Capital
)